Helix BioPharma Shareholders Overwhelmingly Approve All Meeting Items
January 30, 2026 — Helix BioPharma announces 99.99% shareholder approval for all items at its 2026 Annual General Meeting, including director re-elections and share consolidation. Learn about the company's oncology pipeline and clinical progress.